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ABSTRACT  23 
Background: Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly with significant 24 
mortality.  25 
Objectives:  To determine if there were trends in survival over the last decade and to compare patient 26 
populations, treatment options and survival rates between four high-volume centres and hence determine 27 
which factors were associated with survival.  28 
Methods: In four high-volume CDH centres from the CDH EURO Consortium, data from all CDH patients 29 
born between 2004- 2013 were analysed. The predictive value of variables known at birth and the 30 
influence of centre-specific treatments (extracorporeal membrane oxygenation (ECMO) and fetoscopic 31 
tracheal occlusion (FETO)) on survival were evaluated in multivariable logistic regression analyses. 32 
Results: Nine hundred and seventy-five patients were included in the analysis; 274 patients (28.1%) 33 
died. ECMO was performed in 259 patients of whom 81 (31.3%) died. One hundred and forty-five patients 34 
(14.9%) underwent FETO and from those 76 patients (52.4%) survived. Survival differed significantly 35 
between years (p=0.006) and between the four centres (p<0.001). In the multivariable logistic regression 36 
analysis, lung-to-head ratio, gestational age at birth, ECMO, centre of birth, and year of birth were 37 
significantly associated with survival, whereas FETO was not. 38 
Conclusions: Patient populations were different between centres which influenced outcome. There was 39 
a significant variability in survival over time and between centres which should be taken into consideration 40 
in the planning of future trials.  41 
INTRODUCTION 42 
Congenital diaphragmatic hernia (CDH) is a severe congenital anomaly with a high variability of outcome 43 
[1]. Over the last decade new strategies have been introduced to evaluate and manage CDH patients.  It 44 
is likely then that survival may have improved over that time, an aim of our study was to test that 45 
hypothesis.  46 
Patient characteristics such as fetal liver position (intra-abdominal or intrathoracic) [2], stomach position 47 
[3], and lung-to-head ratio (LHR) [4]/ observed-to expected LHR [5] and the diaphragmatic defect size [6] 48 
can influence outcome as well as treatment in a high or low volume centre. There are differences in 49 
opinion about whether extracorporeal membrane oxygenation (ECMO) improves survival as no specific 50 
trials have been conducted with the primary aim of evaluating the role of ECMO specifically for high-risk 51 
CDH patients [7, 8]. The UK ECMO randomised trial investigated the role of ECMO for neonates, but only 52 
19% of those included had CDH and there was no significant difference in that subgroup with regard to 53 
survival [9]. In a multicentre, randomised, clinical trial (RCT) of initial ventilation strategy, in which centres 54 
with and without ECMO availability were included, no difference in survival between centres was 55 
observed [10]. Many CDH centres chose not to use ECMO because of the perceived poor outcome of 56 
CDH infants requiring ECMO [11]. Therefore, an important question is does ECMO influence survival? In 57 
the most severe, prenatally detected CDH cases, fetoscopic endotracheal occlusion (FETO) may improve 58 
outcome [12, 13]. To date, however, the results of only one small RCT have been reported.  In an RCT of 59 
20 severe CDH patients of FETO versus postnatal management, survival was significantly better in the 60 
FETO group [14]. Thus, it is important to further determine the influence of FETO on survival while the 61 
results of the so called TOTAL trial are to be available in 2018. Analysing the results of four high-volume 62 
CDH centres our further aim, therefore, was to compare patient populations, treatment options and 63 
survival rates to determine which factors were associated with survival. 64 
PATIENTS AND METHODS 65 
An observational cohort study was performed of all patients with CDH who were born between January 66 
2004 and December 2013 and treated in four high-volume centres of the CDH EURO Consortium. The 67 
four centres were Rotterdam, London, Mannheim and Rome. Since 2008, all patients have been treated 68 
according to a standardized treatment protocol [15]. The standardized treatment included immediate 69 
intubation after birth, permissive hypercapnia, initial ventilation by high-frequency oscillation or 70 
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conventional mechanical ventilation, surgical repair of the defect after physiological stabilization, no 71 
routine chest tube placement, no routine use of paralysis. ECMO was only used routinely in some 72 
centres. In Rotterdam and Mannheim, ECMO therapy was available during the whole inclusion period, in 73 
Rome ECMO was available in 2013 only and in London infants could be transferred to an ECMO centre.  74 
FETO was available in the four centres on compassionate use.  75 
ECMO criteria were an inability to maintain preductal saturations >85% or postductal saturations >70%; a 76 
high PaCO2 with a respiratory acidosis (pH <7.15) despite optimization of ventilatory management (peak 77 
inspiratory pressure >28 cm H2O or mean airway pressure >17 cm H2O to achieve saturation >85%; 78 
inadequate oxygen delivery with a metabolic acidosis, lactate level >5 mmol/l and pH <7.15); systemic 79 
hypotension, resistant to fluid and inotropic therapy, resulting in urine output <0.5 ml/kg/h for at least 12–80 
24 hours; oxygenation index (mean airway pressure x FiO2 x 100/PaO2) ≥40. Before 2008, in Mannheim, 81 
ECMO criteria included an oxygenation index >35 for 0.5- 6 hours and a pH <7.25. In London, FETO 82 
therapy was only offered within the context of research trials (NCT01240057) from 2013 onwards and 83 
before 2010 as compassionate use. Inclusion criteria for FETO were: isolated left-sided CDH and severe 84 
pulmonary hypoplasia defined as observed-to-expected LHR <25% as measured prior to 29 weeks+ 6 85 
days, irrespective of the liver position. 86 
 87 
Patient demographics and management strategies, including prenatal diagnosis, LHR, FETO, gestational 88 
age, birth weight, gender, side of the defect, liver position (intrathoracic or intra-abdominal determined 89 
during surgical repair), type of repair (primary closure or patch repair), age at surgical repair, ECMO, 90 
ventilation days in survivors, inhaled nitric oxide (iNO) and survival were collected from the medical 91 
records. Death during the first year after birth was determined. 92 
Analysis  93 
To determine whether differences in the demographics of the infants in the four centres were statistically 94 
significant, chi-square tests for categorical data, or Kruskal-Wallis tests for continuous data were used. 95 
Mann-Whitney U tests for continuous data and chi-square tests for categorical data were applied to 96 
compare centre of birth and patient characteristics that were known at birth between survivors and non-97 
survivors. In these univariate comparisons, year of birth was treated as a categorical variable. 98 
Associations between prenatal diagnosis, LHR, FETO, gestational age, gender, side of the defect, 99 
ECMO, centre and year of birth  as independent variables and survival were determined using 100 
multivariable logistic regression analysis. The goodness-of-fit of the logistic regression model was 101 
assessed using the Hosmer-Lemeshow test. Analyses were performed using SPSS 22.0 for Windows 102 
(SPSS, Inc., Chicago, IL).  103 
RESULTS 104 
During the study period, there were 975 CDH patients; 274 (28.1%) patients died. A prenatal diagnosis 105 
was made in 820 (84.1%) patients. Overall, there was a significant difference in survival over the years 106 
(p=0.006) (Figure 1). The survival rate differed from 29% to 97% over the years and centres.  107 
Prenatal diagnosis, LHR, FETO, gestational age, birth weight, gender, liver position at surgical repair, 108 
type of repair, age at surgical repair, ECMO, ventilation days in survivors, use of iNO and survival were 109 
significantly different between the four centres (Table 1). Survivors significantly less often had a prenatal 110 
diagnosis, had higher LHRs and gestational ages and a greater proportion had a left-sided defect than 111 
non-survivors (Table 2).  112 
There were also significant differences in survival regarding year of birth and centre of birth (Table 2). In 113 
Mannheim, 196 patients (41.8%) received ECMO and 153 (78.1%) of the ECMO-treated patients 114 
survived. In Rotterdam, 62 patients (31.8%) received ECMO and 25 (40.3%) of the ECMO-treated 115 
patients survived. ECMO treated patients in Rotterdam had lower LHRs and more often had a patch 116 
repair compared to the ECMO treated patients in Mannheim. In Rome, in 2013 one patient received 117 
ECMO and died. None of the patients from London received ECMO. ECMO use between survivors and 118 
non-survivors was not statistically significant.  FETO was significantly more often used in non-survivors 119 
(25.2%) than in patients who survived (12.5%). 120 
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In the multivariable logistic regression analysis, a lower LHR, lower gestational age, ECMO, centre of 121 
birth and year of birth were significantly associated with death (Table 3). FETO was not significantly 122 
associated with death. The p-value of the Hosmer-Lemeshow test was larger than 0.05, indicating an 123 
adequate model calibration.  124 
DISCUSSION 125 
We have demonstrated variability in survival across a ten year period and between four high volume CDH 126 
centres. In addition, we highlight that the patient populations differed significantly between the centres 127 
and this influenced outcome. The survival rate was very different each year (Figure 1).   128 
In the univariable analysis, we did not find a significant difference in ECMO use between survivors and 129 
non-survivors. In the multivariable analysis with correction for patient characteristics, however, we found 130 
that ECMO was significantly associated with death. This may be explained by the fact that only the most 131 
severe CDH cases receive ECMO. The frequency of use of ECMO and the outcomes was different 132 
between centres. In Mannheim 42% of the patients received ECMO and 78% of them survived, whereas 133 
in Rotterdam 32% of the patients received ECMO and only 41% of them survived. ECMO treated patients 134 
in Rotterdam, however, had lower LHRs and more often had a patch repair, suggesting they were in a 135 
more severe category. To identify for which subgroup of CDH patients ECMO might be most beneficial, 136 
predictive postnatal clinical models such as the Score for Neonatal Acute Physiology-II [16] or the clinical 137 
prediction score by Brindle et al [17] may be useful.  138 
FETO was significantly more often used in non-survivors likely reflecting the selection criteria for 139 
compassionate use. Because FETO was only used on a compassionate basis, it precludes any 140 
meaningful conclusion with regards to the influence of FETO on survival. Hopefully, the TOTAL trial [18] 141 
will give a definitive answer to the benefit of FETO for patients with severe CDH.  142 
High-volume CDH centres have more experience in treating CDH infants than low-volume centres and 143 
better outcomes [19]. Nevertheless, the patient characteristics were very different between the four high-144 
volume centres and, despite correction for patient characteristics in the multivariable analysis, centre 145 
significantly influenced survival. This emphasizes the need for correction for centre in analyses of future 146 
multicentre studies on CDH.   147 
Our study has many strengths and some limitations. We examined the outcome of a large sample 148 
(n=975) over ten years in four high-volume centres. Despite all centres during the study period had 149 
agreed use of a consistent protocol, we cannot rule out the possibility that differences in physicians, 150 
nursing staff and training may have influenced our results. This needs to be taken into account in future 151 
RCTs.  152 
CONCLUSION 153 
We have demonstrated variability in survival of CDH patients over time and between centres. Such 154 
differences need to be taken into account when planning future trials.  155 
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Figure 1. Survival of CDH by centre over the years 227 
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